Researchers at West Virginia University Rockefeller Neuroscience Institute (RNI) have discovered a method to improve delivery of anti-amyloid Alzheimer's treatment across the blood-brain barrier to accelerate the clearance of amyloid-beta plaques.
Anti-amyloid monoclonal antibody treatments have been shown to reduce the amount of...
A new study reviews the volume of advertisements that seniors receive during or around the Medicare enrollment period, and how these reports relate to recent changes in how Medicare Advantage programs will be expected to conduct future advertising campaigns.
The Commonwealth Fund found that "certain marketing experiences reported in ...
The Centers for Medicare and Medicaid Services (CMS) announced the creation of a new payment model for people diagnosed with dementia.
The Guiding an Improved Dementia Experience (GUIDE) Model is an alternative payment model focused on preserving quality of life for diagnosed dementia patients while keeping them at home and providing...
The U.S. Department of Veterans Affairs (VA) has agreed to pay for the Alzheimer's drug Leqembi, putting pressure on the Medicare program to follow suit.
Leqembi, produced by Japanese pharmaceutical manufacturer Eisai Co. in cooperation with Biogen Inc., was approved by the U.S. Food and Drug Administration (FDA) earlier this year....National News
The U.S. Food and Drug Administration (FDA) has approved the drug Leqembi (lecanemab) for the treatment of Alzheimer's disease, but patients will have a difficult time accessing the treatment due to Medicare rules and a hefty price tag.
Leqembi, developed by the Japanese pharmaceutical manufacturer Eisai and its stateside partner...
Over 6 million Americans, including 150,000 Arizonans are currently living with Alzheimer's Disease. As the need for treatment grows, groups like the Alzheimer's Association are asking the government to strengthen its commitment to research and accessibility. But a Congressional report suggests the U.S. Food and Drug Administration (FDA)...
Following approval by the Food and Drug Administration (FDA) last year, the Centers for Medicare and Medicaid (CMS) proposed last month to cover the Alzheimer’s disease drug Aduhelm only for beneficiaries enrolled in a clinical trial. The proposal has sparked fierce debate among insurance groups, drugmakers, policymakers and the...
The Centers for Medicare and Medicaid Services (CMS) proposed Tuesday to cover the controversial drug Aduhelm when used as an Alzheimer’s treatment in clinical trials. While debate about the drug’s safety has been intense, CMS believes continued clinical trials will address unanswered questions related to the drug’s adverse side...National News
This week, Health and Human Services Secretary Xavier Becerra announced the annual update to the Department’s National Plan to Address Alzheimer’s Disease. The update includes a new goal focused on reducing risks that may contribute to the onset of Alzheimer’s disease and promoting healthy aging.
The National Plan to Address...Arizona News
This week Banner Alzheimer’s Institute received a grant expected to total $27.5 million over five years from the National Institute on Aging, part of the National Institutes of Health, to further investigate biological and cognitive changes preceding the onset of memory and thinking problems in people at different levels of genetic...Arizona News
A study designed to help Medicare officials determine if brain scans would be worth covering for Alzheimer’s patients determined that it would not be able to curb healthcare costs.
Advocates still hope they will be able to persuade the agency to support this type of testing but the agency determined it did not support an...Arizona News
Of the 5.7 million Americans living with Alzheimer's dementia, 140,000 are Arizona residents. By 2025, that number is expected to increase by 42.9 percent, up to 200,000 people in Arizona.
The cost of caring for people with Alzheimer's or other dementias will surpass $277 billion nationwide, according to a new report released by the...
